Results 141 to 150 of about 741,475 (253)

Assessment of viral pathogen removal across wastewater treatment stages in a swine processing facility

Australian Veterinary Journal, Volume 104, Issue 11, Page 742-754, November 2026.
A swine abattoir wastewater treatment system in Queensland, Australia, was monitored over 6 months to assess the effectiveness of a pond‐based treatment system for the removal of viruses prior to irrigation reuse. Four viruses were tracked through the facility, from points of entry to the final treated effluent, to identify major sources of viral ...
W Ahmed, M Gebrewold, WJM Smith, K Richards, SL Simpson   +4 more
wiley   +1 more source

Hepatitis risk assessment tool [PDF]

"Hepatitis" means inflammation of the liver and is usually caused by a virus. In the U.S., the most common types are Hepatitis A, Hepatitis B, and Hepatitis C.

core  

Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights From a Decade of Follow‐Up

Hepatology Research, Volume 56, Issue 11, Page 1703-1712, November 2026.
Impairment of health‐related quality of life in patients with PBC, in particular observed in younger female, represents distinct dimensions of disease impact, independently of long‐term outcomes. Overall and interindividual changes in PBC‐40 scores greatly varied over 10 years, suggesting that symptom burdens are driven by heterogeneous underlying ...
Akihito Takeuchi, Atsumasa Komori, Kazuhito Kawata, Osamu Yoshida, Kazunari Tanaka, Kazumichi Abe, Yukihisa Fujinaga, Tadashi Namisaki, Naruhiro Kimura, Tomohiro Katsumi, Ryo Miura, Naoko Tachizawa, Yoshinari Asaoka, Yoshiyuki Ueno, Shuji Terai, Hiromasa Ohira, Hitoshi Yoshiji, Kentaro Kikuchi, Takeshi Matsui, Tadashi Ikegami, Akira Honda, Masanori Abe, Atsushi Tanaka   +22 more
wiley   +1 more source

Hepatic Steatosis in People With Chronic Hepatitis B in Africa: Prevalence, Correlates, and Clinical Significance

Journal of Viral Hepatitis, Volume 33, Issue 11, November 2026.
ABSTRACT To address data gaps around metabolic liver disease in Africa, within the Hepatitis B in Africa Collaborative Network (HEPSANET), we evaluated participants with chronic hepatitis B virus infection (CHB) for steatotic liver disease (SLD) using transient elastography with controlled attenuation parameter (CAP).
Freeman W. Chabala, Edford Sinkala, Alana T. Brennan, Amy Miskimon Goss, Lamin Bojang, Yusupha Samateh, Alexander J. Stockdale, Roger Sombie, Arouna Sessouma, Alice Nanelin Guingane, Juste Aristide Goungounga, Mohamed El‐Kassas, Eman Marwan, Ibrahima Diallo, Abdoul Sow, Edith Okeke, Attah Okwute, Hans Prozesky, Zahiera Ismail, Mark Sonderup, C. Wendy Spearman, Philippa C. Matthews, Judicaël Malick Tine, Maud Lemoine, Hailemichael Desalegn Mekonnen, Asgeir Johnannessen, Michael J. Vinikoor, on behalf of Hepatitis B in Africa Collaborative Network (HEPSANET), Alice Guingane, Roger Sombie, Asgeir Johannessen, Edith Okeke, Mohamed El‐Kassas, Gilles Wandeler, Ibrahima Diallo, Joan Rugemalila, Wendy Spearman, Hans Prozesky, Alex Stockdale, Maud Lemoine, Babatunde Duduyemi, Mary Afihene, Edford Sinkala, Asgeir Johannessen, Roger Sombie, Alex Stockdale, Alice Guingane, Michael Vinikoor, Edith Okeke, Maud Lemoine, Philippa Matthews, Wendy Spearman, Adria Ramirez   +52 more
wiley   +1 more source

Hepatitis delta [PDF]

Revista Española de Enfermedades Digestivas, 2007
Romero-Portales, M., García-Samaniego Rey, J.   +1 more
openaire   +4 more sources

Multitarget Drug Design for Cardiovascular Disease: Bridging Chemistry and Medicine

ChemMedChem, Volume 21, Issue 19, 14 October 2026.
Many pathophysiological pathways associated with cardiovascular diseases involve multiple drug targets. This article reviews recent advances in the development of pharmacological compounds capable of simultaneously modulating multiple mechanisms. Multitarget drugs offer a promising therapeutic approach for complex cardiovascular disorders, including ...
Gyuzel Y. Mitronova, Vladimir N. Belov, Constanze Schmidt, Stephan E. Lehnart   +3 more
wiley   +1 more source

Hitting Coronaviruses Where It Hurts: Antiviral Strategies Targeting Viral Proteins

ChemMedChem, Volume 21, Issue 19, 14 October 2026.
Viral proteins represent key vulnerabilities in human coronaviruses (HCoVs). This review outlines inhibitors targeting spike (S), main protease (Mpro), papain‐like protease (PLpro), and RNA‐dependent RNA polymerase (RdRp), mapping chemically diverse strategies that disrupt entry and replication, and provides an integrated view of current candidates ...
Álvaro de la Cruz‐Potenciano, Miguel Maldonado, María‐José Camarasa, Sonia de Castro   +3 more
wiley   +1 more source

Bulevirtide for Chronic Hepatitis Delta

Gastroenterology, 2023
openaire   +3 more sources

Frequency of CAP-Defined Hepatic Steatosis and Its Association with Liver Fibrosis in Patients with Hepatitis Delta. [PDF]

Viruses
Mermutluoğlu Ç, Dayan S, Demir Y, Mete AÖ, Çelen MK.   +4 more
europepmc   +1 more source

FDA approval of hepcludex: a milestone in the treatment of chronic hepatitis delta virus infection. [PDF]

Ann Med Surg (Lond)
Fatima E, Oduoye MO.
europepmc   +1 more source